Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?
{{output}}
In parametric Bayesian designs of early phase cancer clinical trials with drug combinations exploring a discrete set of partially ordered doses, several authors claimed that there is no added value in including an interaction term to model synergism between th... ...
